Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Mon, 9 Dec 01:30 pm

Indian share markets continued to rule firm in the post-noon trading session. Barring consumer durables, all the sectoral indices are trading in the green with banking, capital goods and realty stocks being the biggest gainers.

BSE-Sensex is up 323 points and NSE-Nifty is trading 99 points up. BSE Mid Cap is trading up 0.86% and BSE Small Cap index is trading up 0.3%. The rupee is trading at 61.1 to the US dollar.

Majority of the Automobile stocks are trading in the green with Mahindra & Mahindra (M&M) and Maruti Suzuki being the major gainers whereas Force Motors and Eicher Motors are trading in the red. As per a leading financial daily, M&M would be making capital investments of Rs 75 bn over the next three years across its diverse business segments. The magnitude of investments in the agriculture segment will be small as compared to investments in the automobile and tractor segments. The company wants to expand its presence in the agriculture business by launching mechanization products such as rice transplanters developed in India and a new series of rotavators that are essentially tractor-drawn equipments. In the micro-irrigation segment, M&M is exploring technological tie-ups with foreign companies. The company already has micro-irrigation products company EPC industries under its portfolio that it wants to scale up further. M&M stock is currently trading up by 2%.

Stocks from the healthcare sector are largely trading firm with Dr. Reddy's Laboratories and Sun Pharmaceuticals leading the pack of gainers while Apollo Hospitals and Cipla are trading weak. A leading business daily has reported that Glenmark Pharmaceuticals has launched an anti-inflammatory cream in the US market. It has done this through its US based subsidiary Glenmark Generics Inc. This cream – which is a generic version of Locoid Lipocream - is used to treat dermatoses in adults and moderate dermatitis (skin inflammations) in patients under the age of eighteen. The company had received approval for launching the generic version in September this year. This is a positive development for the company as it would enjoy a 180 day exclusivity being the first to launch the generic version of this Hydrocortisone Butyrate cream. The sales of this cream stood at about US$ 37 m (about Rs 2.3 bn) in the US only in the past twelve months, thereby giving a sense of the market size.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.